NEW YORK (360Dx) – Dutch biotech firm SkylineDx said on Thursday that it has been awarded a €2.7 million ($3.1 million) loan for further development of its skin cancer test.
The loan is from the Netherlands Enterprise Agency, which is part of the Ministry of Economic Affairs and Climate Policy. Using genetic information from cancer cells, SkylineDx is developing its test to predict whether a patient is at risk of having metastases in the lymph nodes, it said.
The Rotterdam, Netherlands-based company is developing the test in collaboration with the research group of Mayo Clinic researcher Alexander Meves. SkylineDx CEO Dharminder Chahal said in a statement that the partners are close to starting their first clinical validation trials for the test.